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ABSTRACT
Antimicrobial agents may interact synergistically. But to ensure
synergy in vivo, the drugs should both be present at the site of
infection at sufficiently high concentrations for an adequate
period of time. Coencapsulation of the drugs in a drug carrier
may ensure parallel tissue distributions. Since liposomes local-
ize preferentially at sites of infection, this mode of drug delivery
could, in addition, increase drug concentrations at the focus of
infection. The therapeutic efficacy of gentamicin and ceftazi-
dime coencapsulated into liposomes was examined by moni-
toring survival in a rat model of an acute unilateral pneumonia
caused by antibiotic-susceptible and antibiotic-resistant Kleb-
siella pneumoniae strains. It is shown that administration of
gentamicin in combination with ceftazidime in the free form
either as single dose or as 5-day treatment resulted in an
additive effect on rat survival in both models. In contrast, tar-
geted delivery of liposome-coencapsulated gentamicin and
ceftazidime resulted in a synergistic interaction of the antibiot-
ics in both models. Consequently, liposome coencapsulation of
gentamicin and ceftazidime allowed both a shorter course of
treatment at lower cumulative doses compared with adminis-
tration of the antibiotics in the free form to obtain complete
survival of rats. Liposomal coencapsulation of synergistic anti-
biotics may open new perspectives in the treatment of severe
infections.
Administration of combinations of antimicrobial agents is
frequently used in clinical practice to increase therapeutic
efficacy. Efficacy may be increased by broadening the anti-
microbial spectrum of the treatment, preventing the emer-
gence of resistant strains, reducing toxicity, eliminating mul-
tiresistant microorganisms, and/or enhancing bacterial
killing by exploiting the synergistic interaction of a specific
drug combination (Barriere, 1992; Schimpff, 1993; Shlaes et
al., 1993). To ensure a synergistic drug interaction in vivo,
the drugs should both be present at the site of infection at
sufficiently high concentrations for an adequate period of
time (Den Hollander et al., 1998; Join-Lambert et al., 1998;
Strenkoski-Nix et al., 1998; Mouton et al., 1999). Due to the
differences in physicochemical properties between the vari-
ous antimicrobial agents, the pharmacokinetics and tissue
distributions of these agents vary substantially. A significant
interaction of antibiotics at the infectious focus resulting in a
synergistic activity is therefore not guaranteed. The use of a
drug carrier containing both antibiotics could enforce a par-
allel tissue distribution of both of the encapsulated agents. In
addition, the use of a targeted drug carrier (including lipo-
somes) may increase the concentrations of the drugs at the
site of infection, which would further strengthen the syner-
gistic drug interaction. In this respect, coencapsulation of
antibiotics in liposomes may open new perspectives.
Liposomes have been widely investigated as targeted drug
carriers in infectious diseases. Liposomes have been shown to
localize selectively at the infected target site in a variety of
experimental models of infection (Oyen et al., 1996; Awasthi
et al., 1998a,b; Dams et al., 1999a,b; Schiffelers et al., 1999).
The selective localization appears to be the result of the
locally increased capillary permeability allowing local lipo-
some extravasation (Allen, 1997; Boerman et al., 1998). Up to
now, only liposomes containing a single antimicrobial agent
have been investigated. The aim of the present study was to
coencapsulate two antibiotics, gentamicin and ceftazidime,
that have documented synergy in vitro (Giamarellou et al.,
1984) into liposomes and examine their therapeutic efficacy
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in vivo by monitoring survival in a rat model of an acute
unilateral Klebsiella pneumoniae pneumonia. Both an anti-
biotic-susceptible and an antibiotic-resistant K. pneumoniae
strain were studied.
Materials and Methods
Liposome Preparation. Polyethylene glycol-coated long-circu-
lating liposomes were used, as previous studies have demonstrated
that this liposome type shows substantial localization at the site of
infection in the investigated model (Schiffelers et al., 1999). Lipo-
somes were prepared as described previously (Schiffelers et al.,
1999). Appropriate amounts of the indicated lipids partially hydro-
genated egg phosphatidylcholine (Asahi Chemical Industry Co. Ltd.,
Ibarakiken, Japan), cholesterol (Sigma Chemical Co., St. Louis, MO),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[polyethylene
glycol-2000] (Avanti Polar Lipids, Alabaster, AL) in a molar ratio of
1.85:1.00:0.15, respectively, were dissolved in a mixture of chloro-
form and methanol. After evaporation of the solvent under constant
rotation and reduced pressure, the lipid mixture was dried under
nitrogen, dissolved in 2-methyl-2-propanol (Sigma Chemical Co.)
frozen by immersing in ethanol (240°C), and freeze-dried overnight.
The resulting lipid film was hydrated for 2 h in aqueous solutions of
appropriate concentrations of ceftazidime (CZ) (Glaxo-Wellcome,
Zeist, The Netherlands) or gentamicin (GN) (Duchefa Biochemie,
Haarlem, The Netherlands). For coencapsulation of the drugs in
liposomes, the CZ solution was added first, followed by the GN
solution. Lipid concentration was diluted to a final concentration of
100 mmol of total lipid per milliliter using Hepes/NaCl buffer pH 7.4
(10 mM Hepes) (Sigma Chemical Co.) and 135 mM NaCl (Merck,
Darmstadt, Germany). The lipids were sonicated for 8 min with an
amplitude of 8 mm using a 9.5-mm probe in an MSE Soniprep 150
(Sanyo Gallenkamp PLC, Leicester, UK) to obtain long-circulating
liposomes with a mean particle size of 100 nm. Particle size distri-
bution was measured using dynamic light scattering, detected at an
angle of 90° to the laser beam on a Malvern 4700 System (Malvern
Instruments Ltd., Malvern, UK). In addition to the mean particle
size, the system reports a polydispersity index (a value between 0
and 1). A polydispersity index of 1 indicates large variations in
particle size, a reported value of 0 means that size variation is
apparently absent. All liposome preparations used had a polydisper-
sity index below 0.3. Unencapsulated GN and/or CZ was removed by
ultracentrifugation of the liposomes in two changes of Hepes/NaCl
buffer at 265,000g for 2 h at 4°C. Phosphate concentration was
determined spectrophotometrically according to Bartlett (Bartlett,
1959). Total (liposome-encapsulated and free) and free (unencapsu-
lated) GN and/or CZ was measured using a diagnostic sensitivity test
agar (Oxoid, Basingstoke, UK) diffusion test with Staphylococcus
aureus Oxford strain (ATCC 9144) (CZ-resistant) and an Escherichia
coli strain (clinical isolate, GN-resistant) as the indicator organism
for GN and CZ, respectively, as described previously (Bakker-
Woudenberg et al., 1995). For total (unencapsulated and encapsu-
lated) drug measurements, liposomes were disintegrated by 0.1% v/v
(final concentration) Triton X-100 (Janssen Chimica, Geel, Belgium).
Less than 10% of the GN and/or CZ was shown to be unencapsulated
after ultracentrifugation. The validity of the agar diffusion test for
the determination GN and CZ concentrations in the combination was
ascertained in a separate experiment. Enzymatic inactivation of GN
using aminoglycoside-acetylating enzyme (Den Hollander et al.,
1996) or of CZ using b-lactamase (Koch-Light Ltd., Haverhill, UK)
yielded similar inhibitory zones as without deactivation of either one
of the antibiotics, thus showing the possibility to measure one drug
at a time in the combination.
Bacterial Strains. The susceptible K. pneumoniae (ATCC 43816,
capsular serotype 2, MIC 5 0.5 mg/ml for both GN and CZ) was used.
The MIC was determined by plating an inoculum of 104 cfu/spot on
Mueller-Hinton agar (Difco, Detroit, MI) plates containing 2-fold
dilutions of GN or CZ, according to Woods and Washington (1995).
The resistant K. pneumoniae (MIC 5 32 mg/ml for GN and 16 mg/ml
for CZ) was obtained by culturing the susceptible strain in Mueller-
Hinton broth (Difco) containing increasing concentrations of CZ. The
MIC was determined according to the method described above. The
resulting CZ-resistant strain was conjugated with an E. coli R176
strain (clinical isolate) that produced a plasmid encoding for an
aminoglycoside-acetylating enzyme. In this way, a strain resistant to
both GN and CZ was obtained. The stability of the GN/CZ-resistant
phenotype in vitro was checked by culturing the bacteria five times
in succession in antibiotic-free medium, followed by determination of
the MIC. All of 100 tested bacterial colonies remained resistant to
both antibiotics.
Checkerboard Titrations. Checkerboard titrations were per-
formed with GN and/or CZ at the indicated concentrations in Muel-
ler-Hinton broth of 37°C in a total volume of 3 ml. An inoculum of 5 3
105 susceptible or resistant K. pneumoniae cfu/ml in the logarithmic
phase of growth was used. Tubes were incubated for 24 h at 37°C,
and (the absence of) microbial growth was determined macroscopi-
cally. Each titration was performed in triplicate.
Time-Kill Curves. Time-kill curves were performed with GN
and/or CZ at the indicated concentrations in Mueller-Hinton broth of
37°C in a total volume of 3 ml. An inoculum of 5 3 105 susceptible or
resistant K. pneumoniae cfu/ml in the logarithmic phase of growth
was used. Samples were taken at 0, 1, 2, 4, 6, and 24 h after addition
of the inoculum. Number of bacteria in the samples was determined
by making serial dilutions in phosphate-buffered saline 4°C. Two
hundred microliters of each dilution was plated on tryptone soy agar
plates and incubated overnight at 37°C. Colonies were counted. Each
curve was determined in triplicate.
Unilateral Pneumonia. The animal experiments ethical com-
mittee of the Erasmus University Medical Center Rotterdam ap-
proved the experiments described in this study. Female albino RP/
AEur/RijHsd strain albino rats, 18 to 25 weeks of age, body weight
185 to 225 g (Harlan, Horst, The Netherlands) with a specified
pathogen-free status were used. A left-sided unilateral pneumonia
was induced as described previously (Bakker-Woudenberg et al.,
1982). In brief, rats were anesthetized and the left primary bronchus
was intubated. Through the tube, 0.02 ml of a saline suspension
containing 106 susceptible K. pneumoniae was inoculated. Inoculated
bacteria were in the logarithmic phase of growth. For the resistant K.
pneumoniae strain the inoculum was adjusted to 2 3 108 to establish
a median survival of untreated controls that was comparable be-
tween both models. Rats were housed individually. In vivo stability
of the phenotype of the K. pneumoniae was checked by culturing
dilutions of homogenized left lung tissue obtained at 24 h after
bacterial inoculation (the starting point of therapy) on Mueller-
Hinton plates. Colonies were isolated and MIC was determined as
described above on Mueller-Hinton plates. All of 100 tested colonies
of both the susceptible and resistant strain had a stable phenotype,
regarding GN and CZ-susceptibility, after inoculation in vivo.
Treatment was started at 24 h after bacterial inoculation. Con-
trols were left untreated. GN and/or CZ was administered either as
a single dose or as multiple doses every 12 h. In case of combination
of GN and CZ, the drugs were injected with an interval of 5 min.
Liposome-encapsulated gentamicin or ceftazidime (LE-GN or LE-CZ,
respectively) or liposome-coencapsulated gentamicin and ceftazi-
dime (LE-GN-CZ) was administered either as a single dose or as
multiple doses every 24 h. The formulations were injected intrave-
nously into the tail vein. Survival of rats was examined every day
until 14 days after bacterial inoculation. The MIC of the K. pneumo-
nia bacteria recovered from deceased rats was determined as de-
scribed above and similar to that of the inoculated bacteria.
Statistical Analysis. To identify synergy, in vitro and in vivo, the
effect of a drug combination was compared with the expected effect
for each of the drugs alone. This method to identify synergy, also
known as the isobole or iso-effect curve-method, has been validated
by Berenbaum (1989). The method is based on the equation da/Da 1
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db/Db 5 I, where Da and Db are the doses of agent A alone and agent
B alone, respectively, needed to produce a desired effect. The terms
da and db are the doses in a combination of agent A and agent B,
respectively, that produce the same effect (iso-effect). If no interac-
tion between agent A and agent B is present, or in other words the
effects of agent A and agent B are additive, the interaction index
(I) 5 1. Deviations indicate synergy (I , 1) or antagonism (I . 1).
Curves, resulting from the checkerboard titrations were compared
with lines describing absence of drug interaction using the F test.
Survival between experimental groups was compared by the log-
rank test. Area under the time-kill curve (AUKC) was calculated
using the trapezoid rule. Analyses were performed using GraphPad
Prism 3.00 software (GraphPad Software Inc., San Diego, CA).
AUKCs were compared by one-way analysis of variance (ANOVA)
corrected for multiple comparisons using the Bonferroni method.
Results
Checkerboard Titrations. The results of the checker-
board titrations with the susceptible strain and resistant
strain are shown in Fig. 1, A and B, respectively. The shape
of the best-fitted curve in Fig. 1, A and B, is concave up and
describes the relationship significantly better than the line
that would represent the relationship in absence of drug
interactions (F test, p , 0.0001 for both curves). Thus, CZ
and GN act synergistically against both K. pneumoniae
strains.
Time-Kill Curves. The time-kill curves of the susceptible
strain and the resistant strain are shown in Fig. 2, A and B,
respectively. Bacterial density for both strains rapidly in-
creased to a plateau of 109 bacteria/ml in absence of antibi-
otics. For the susceptible strain, GN alone, at a concentration
of 0.3 mg/ml, initially reduced bacterial numbers. After 4 h of
incubation .99% of bacteria were killed. However, between 6
and 24 h of incubation, bacterial outgrowth was observed to
107 bacteria/ml. Similar results were obtained with CZ alone
at a concentration of 0.3 mg/ml. Incubation of 0.15 mg/ml GN
and 0.15 mg/ml CZ in combination reduced bacterial numbers
more efficiently. After 4 h of incubation .99.99% of bacteria
were killed, whereas after 24 h of incubation the bacterial
density was 105-fold lower compared with the single agent
incubations. The AUKC values of the time-kill curves are
shown in Table 1. As the AUKC value of the combination is
significantly lower than the AUKCs of the single agent incu-
bations (ANOVA, p , 0.05 for both GN and CZ), and thus
dGN/DGN 1 dCZ/DCZ , 1, it can be concluded that GN and CZ
display a synergistic interaction against the susceptible K.
pneumoniae (Berenbaum, 1989).
For the resistant strain, GN alone, at a concentration of 16
mg/ml, initially stabilized bacterial numbers, but at 24 h after
incubation bacterial density had increased to the control
level. CZ alone, 8 mg/ml, also stabilized bacterial counts ini-
tially, but eventually bacterial outgrowth was observed to
107 bacteria/ml after 24 h of incubation. The combination of
GN and CZ at concentrations of 8 and 4 mg/ml, respectively,
initially killed and then stabilized bacterial counts through-
out the study period of 24 h. As the AUKC value of the
combination was significantly lower compared with those of
the single agent incubations (ANOVA, p , 0.001), and thus
dGN/DGN 1 dCZ/DCZ , 1, GN and CZ showed a synergistic
interaction against the resistant K. pneumoniae (Table 1).
Rat Survival in Susceptible K. pneumoniae Pneumo-
nia Model. The results of the in vivo survival experiments
with rats infected with the susceptible K. pneumoniae are
shown in Fig. 3. Maximum survival after a single dose of free
GN alone or free CZ alone was 50% (Fig. 3A). The maximum
dose for free GN alone was 20 mg/kg and for free CZ alone
200 mg/kg, because 2-fold higher doses caused acute toxicity
(local irritation at the site of injection for CZ and convulsions
for GN). As the combination of free GN and free CZ did not
increase survival compared with an equivalent dose of free
GN alone or free CZ alone, dGN/DGN 1 dCZ/DCZ . 1, which
would suggest antagonism. However, as the single dose
treatment never resulted in survival .50%, these data seem
more indicative for the conclusion that treatment is too short
to have sufficiently prolonged concentrations at the site of
infection for the drugs to exert their maximum effect on rat
survival.
By prolonging treatment to 5 days and administering the
antibiotics every 12 h, survival is increased (Fig. 3B). Free
GN alone showed a steep dose-response relation between
0.63 mg/kg/day (0% survival) and 1.25 mg/kg/day (100% sur-
vival), explaining why intermediate drug doses were also
studied. Free CZ alone showed a response of 0% survival up
to 100% at doses ranging from 12.5 to 100 mg/kg/day. Look-
ing at iso-effective doses of free GN alone and free CZ alone
(e.g., 1.05 mg GN/kg/day and 50 mg CZ/kg/day), each result-
ing in 60 to 70% survival, shows that combination of half of
these iso-effective doses for free GN and free CZ (i.e., 0.53 mg
GN/kg/day combined with 25 mg CZ/kg/day) results in a
similar survival percentage (60%). As a result, dGN/DGN 1
dCZ/DCZ ’ 1, indicating that there is no interaction between
free GN and free CZ in vivo at the 5-day treatment schedule.
Using the liposome-encapsulated antibiotics, the survival
data obtained with single doses of either LE-GN alone,
LE-CZ alone, or coencapsulated LE-GN-CZ were completely
different (Fig. 3C). A single dose of LE-GN alone produced a
dose response with 0% survival at a dose of 1.25 mg/kg,
increasing to complete survival for the 20-mg/kg dose.
Whereas with LE-CZ, 0% survival was obtained after admin-
istration of 0.38 mg/kg. Survival increased gradually to 100%
for 12 mg/kg. Looking at iso-effective doses for LE-GN and
LE-CZ alone (e.g., 5 mg of LE-GN/kg or 3 mg LE-CZ/kg) each
resulting in 60 to 67% survival, shows that coencapsulation
of half of these iso-effective doses (i.e., LE-GN-CZ 2.5/1.5
mg/kg, respectively) showed a significantly better survival
(100%) (Log-rank test, p , 0.05). Consequently, dLE-GN/
Fig. 1. Checkerboard titrations of GN and CZ against the susceptible K.
pneumoniae (A) and the resistant K. pneumoniae (B). The symbols rep-
resent the lowest concentrations of GN and CZ that resulted in absence of
bacterial growth. The curve shows the best fit through the symbols,
whereas the dotted line represents the relationship that would be ob-
tained in absence of drug interactions. Both experiments were performed
in triplicate.
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DLE-GN 1 dLE-CZ/DLE-CZ , 1, revealing a synergistic interac-
tion of liposome-coencapsulated GN and CZ.
Rat Survival in Resistant K. pneumoniae Pneumonia
Model. The results of the in vivo survival experiments with
rats infected with the resistant K. pneumoniae are shown in
Fig. 4. Administration of single doses of the free drugs, alone
or in combination, at the maximum tolerated dose did not
yield survival (data not shown). Prolongation of treatment to
5 days with the free drugs administered every 12 h increased
survival. Yet, free GN alone at the maximum tolerated dose
of 40 mg/kg/day showed only 40% survival. With free CZ
alone a nearly complete dose-response relation could be ob-
tained at doses ranging from 50 (0% survival) to 400 mg/kg/
day (90% survival). Looking at iso-effective doses of free GN
alone and free CZ alone (e.g., 40 mg GN/kg/day or 100–200
mg CZ/kg/day) each resulting in 30 to 50% survival, shows
that combination of half of these iso-effective doses of GN and
CZ (i.e., 20 mg GN/kg/day combined with 50 or 100 mg
CZ/kg/day) did not increase the survival percentage signifi-
cantly (20–70%) (Fig. 4A). Consequently, dGN/DGN 1 dCZ/
DCZ ’ 1, indicating that there is no interaction between free
GN and free CZ.
In contrast, treatment for only 2 days with LE-CZ alone
showed 0% survival at a dose of 3 mg/kg/day, and complete
survival was already obtained at a dose of 24 mg/kg/day.
LE-GN alone at the maximum administered dose of 40 mg/
kg/day did not produce survival. However, at this dose of 40
mg/kg LE-GN survival of rats was significantly prolonged
compared with the controls (p , 0.01). Liposomal coencapsu-
lation of GN and CZ improved survival compared with
LE-GN alone or LE-CZ alone. LE-GN-CZ, at a dose of 10 and
12 mg/kg/day, respectively, already produced complete sur-
vival, which was obtained for LE-CZ alone at 24 mg/kg/day
and for LE-GN alone at a dose that exceeded 40 mg/kg/day
(probably by far) (Fig. 4B). Consequently, dLE-GN/DLE-GN 1
dLE-CZ/DLE-CZ , 1, thus showing a synergistic interaction of
liposome-coencapsulated GN and CZ. Similar reasoning
shows a synergistic interaction for LE-GN-CZ at doses of 10
combined with 6 mg/kg/day as well as 10 combined with 3
mg/kg/day CZ, respectively.
Discussion
Treatment with a combination of antimicrobial agents may
improve therapeutic efficacy over single agent treatment as a
result of synergistic drug interactions. Synergistic drug in-
teraction in vitro has been clearly shown for various drug
combinations. For a synergistic drug interaction to occur in
vivo, the drugs in the combination should be present at the
site of infection at sufficiently high concentrations for an
adequate period of time. Theoretically, simultaneous drug
delivery to the target site could strengthen synergistic inter-
actions. Interestingly in this respect, targeted liposomal de-
livery of single antimicrobial agents has demonstrated supe-
rior therapeutic efficacy over conventional antimicrobial
treatment in a number of experimental infection models
(Wasan and Lopez-Berestein, 1995; Bergers et al., 1995;
Fielding et al., 1998). The superior efficacy is attributable to
the increased concentration of the drug at the site of infection
as a result of the targeted drug delivery. Up to now, only
Fig. 2. Time-kill curves of the susceptible K. pneumoniae (A) and the resistant K. pneumoniae (B). A, susceptible bacteria were incubated without
antibiotics (F), 0.3 mg/ml GN (), 0.3 mg/ml CZ (), or 0.15 mg/ml GN in combination with 0.15 mg/ml CZ (E). B, resistant bacteria were incubated
without antibiotics (F), 16 mg/ml GN (), 8 mg/ml CZ (), or 8 mg/ml GN in combination with 4 mg/ml CZ (E). Both experiments were performed in
triplicate.
TABLE 1
Log AUKC values for the susceptible and the resistant K. pneumoniae strain
Bacteria were incubated with indicated concentrations of GN, CZ, or GN in combination with CZ.
Susceptible Resistant
Drug (mg/ml) AUKCa Drug (mg/ml) AUKCa
log no. bacteria 3 h/ml log no. bacteria 3 h/ml
Control 10.4 6 0.1*** Control 10.2 6 0.1***
GN (0.3) 8.9 6 1.7* GN (16) 9.9 6 0.1***
CZ (0.3) 8.2 6 0.6* CZ (8) 8.3 6 0.1***
GN/CZ (0.15/0.15) 5.9 6 0.2 GN/CZ (8/4) 7.0 6 0.2
a Experiment was performed in triplicate. Results are expressed as mean 6 S.D. ANOVA corrected for multiple comparisons using the Bonferroni method, significant
differences compared with the combination regimen are noted as *** p , 0.001, * p , 0.05.
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single agent liposome preparations have been investigated.
The present study aimed to investigate the therapeutic effi-
cacy of liposome-coencapsulated antimicrobial agents in vivo
in a rat model of pneumonia caused by an antibiotic-suscep-
tible strain or antibiotic-resistant strain of K. pneumoniae.
The results of the present study show that targeted liposomal
delivery of GN and CZ results in a synergistic interaction of
these antibiotics in vivo. Importantly, the synergistic inter-
action was present in the animals infected with the suscep-
tible strain as well as the animals infected with the resistant
strain. In contrast, administration of the combination of the
antibiotics in the free form, although showing synergy in
vitro, displayed only an additive effect in both in vivo models.
Synergy in vivo was not observed. As a result, by use of
liposome-coencapsulated GN and CZ, 100% survival can be
obtained using a shorter treatment schedule and lower total
drug exposure compared with treatment with the free drugs.
The interaction between GN and CZ against both the sus-
ceptible and resistant K. pneumoniae was first examined in
vitro by performing checkerboard-titrations and time-kill ex-
periments. Both in vitro assays show that GN and CZ acted
synergistically against both the susceptible strain and the
resistant K. pneumoniae strain. The in vitro synergistic in-
Fig. 3. Percentage of rat survival at 14 days after inoculation of the
susceptible K. pneumoniae in the left lung. Rats were treated at 24 h after
bacterial inoculation with a single dose of free GN (M), free CZ (u), or GN
and CZ (f) (A); 10 doses every 12 h of GN (M), CZ (gray bars), or GN and
CZ (f) (B); single dose of LE-GN (M), LE-CZ (u), or LE-GN-CZ (f) (C).
Number of animals per experimental group in italics.
Fig. 4. Percentage of rat survival at 14 days after inoculation of the
resistant K. pneumoniae in the left lung. Rats were treated at 24 h after
bacterial inoculation with 10 doses every 12 h of free GN (M), CZ (u), or
GN and CZ (f) (A); two doses every 24 h of LE-GN (M), LE-CZ (u), or
LE-GN-CZ (f) (B). Number of animals per experimental group in italics.
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teraction of GN and CZ, or in general aminoglycosides and
b-lactam antibiotics, has been reported earlier. The interac-
tion is suggested to be due to the limited penetration of
aminoglycosides into bacteria to effect bacterial killing and
the ability of b-lactams to increase that penetration (Davis,
1982).
To investigate whether GN and CZ can act synergistically
in vivo, rats were infected with either the susceptible or the
resistant K. pneumoniae strain, and survival was monitored
for 14 days. At single doses of either free GN alone or free CZ
alone a maximum survival of 50% could be obtained in rats
infected with the susceptible strain. Combination of single
doses of free GN and free CZ did not improve survival com-
pared with an equivalent single dose of either free GN alone
or free CZ alone. Likely, treatment at a single dose of GN and
CZ is too short and thus adequate concentrations at the site
of infection are too transient for synergistic interactions to
have an effect on survival.
To increase therapeutic efficacy, treatment with the free
drugs was prolonged to 5 days and both antibiotics were
administered every 12 h. Using this dosing schedule, com-
plete survival could be obtained with either free GN alone or
free CZ alone against the susceptible K. pneumoniae infec-
tion. The effects of free GN combined with free CZ on rat
survival in this 5-day treatment schedule, however, are
merely additive. Synergism was not detected. This result was
unexpected as, in vitro, GN and CZ acted synergistically
against both K. pneumoniae strains and synergism between
aminoglycosides and b-lactams in vivo has been reported
(Pefanis et al., 1993; Mimoz et al., 1998). The discrepancy
between in vitro and in vivo data is possibly the result of the
rapidly changing concentrations of the antibiotics at the site
of infection in the rats compared with the constant drug
concentrations in the in vitro incubations (Den Hollander et
al., 1998; Join-Lambert et al., 1998). Seemingly, the pharma-
cokinetics and tissue distributions of free GN and free CZ in
rats (Acred, 1983; Nassberger and De Pierre, 1986; Swenson
et al., 1990; Granero et al., 1998) do not provide adequate
drug concentrations at the site of the K. pneumoniae infection
in a timely manner for synergistic drug interactions to occur.
Consequently, the assessment of in vitro synergistic interac-
tions does not guarantee in vivo synergy to occur predictably.
The results obtained with the liposome-encapsulated anti-
biotics contrast favorably with the results obtained with the
free antimicrobial agents. Single doses of LE-GN alone or
LE-CZ alone were shown to be highly effective, as complete
survival could be obtained in the susceptible K. pneumoniae
infection. Apparently, the simultaneous targeted delivery of
LE-GN-CZ results in higher GN and CZ concentrations at the
target site for prolonged periods of time, enabling synergistic
drug interactions to occur. A single dose of liposomal coen-
capsulated agents produced complete survival at a compara-
ble GN-exposure and a 170-fold reduced CZ body exposure,
compared with 10 injections of the free drug combination.
To investigate the strength of the synergistic drug inter-
action after administration in the coencapsulated form, com-
parative studies were also performed in rats infected with
the resistant K. pneumoniae strain. In this model, survival in
a 5-day treatment schedule could only be obtained with doses
of free GN alone or free CZ alone that were well over the
clinically recommended doses. Combinations of free GN with
free CZ were again just additive. In contrast, administration
of two doses of LE-CZ alone of 24 mg/kg/day already resulted
in complete survival. LE-GN alone was less effective as two
doses of 40 mg/kg/day failed to increase survival. Yet, lipo-
some-coencapsulation of GN and CZ resulted in significantly
improved survival compared with the expected efficacy based
on the dose-response relations of LE-GN alone and LE-CZ
alone, demonstrating that the synergistic interaction was
strong enough to overcome infection with a resistant K. pneu-
moniae infection. Two doses of liposome-coencapsulated GN
and CZ produced complete survival at a 10-fold lower GN
exposure and 40-fold lower CZ exposure compared with 10
injections of the free GN-CZ combination.
In conclusion, the present study demonstrates that tar-
geted delivery of GN and CZ by liposome-coencapsulation
results in synergistic drug interactions in a susceptible as
well as resistant K. pneumoniae pneumonia model. In these
models, synergistic interaction of a combination of free GN
and free CZ could not be demonstrated. The application of
multiple antimicrobial agents coencapsulated into liposomes
could be a valuable contribution to the treatment of severe
bacterial infections.
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